Ipsen
Ipsen S.A. is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France, specializing in the development and commercialization of innovative medicines. The company operates in two main segments: Specialty Care and Consumer Healthcare. Ipsen's therapeutic focus includes oncology, neuroscience, pituitary disorders, gastrointestinal conditions, and rare diseases. Its oncology portfolio features treatments such as Somatuline for neuroendocrine tumors, Cabometyx for renal cell carcinoma, and Onivyde for metastatic pancreatic cancer. In neuroscience, Ipsen provides therapies for growth disorders and neurodegenerative conditions, including NutropinAq and Dysport. Additionally, the company offers various consumer healthcare products for gastrointestinal issues and pain management. Founded in 1929, Ipsen is dedicated to innovation and has established collaborations with notable organizations, enhancing its research and development capabilities.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
25 past transactions
Albireo Pharma
Acquisition in 2023
Albireo Pharma, Inc. is a biopharmaceutical company based in Boston, Massachusetts, specializing in the development and commercialization of innovative bile acid modulators aimed at treating rare pediatric liver diseases and gastrointestinal disorders. The company's lead product candidate, odevixibat, is an ileal bile acid transporter inhibitor currently undergoing phase III clinical trials for the treatment of progressive familial intrahepatic cholestasis, biliary atresia, alagille syndrome, and other cholestatic liver diseases. Additionally, Albireo is advancing Elobixibat, which targets chronic constipation and other functional gastrointestinal disorders, as well as nonalcoholic steatohepatitis. The company is also developing A3384 for gastrointestinal diseases and has established a licensing agreement with EA Pharma for the development and commercialization of elobixibat.
Epizyme
Acquisition in 2022
Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to the discovery, development, and commercialization of innovative epigenetic medicines for cancer and other serious diseases. Founded in 2007, the company has developed Tazemetostat, an approved treatment for metastatic or locally advanced epithelioid sarcoma, and is exploring its use in various combinations for other malignancies, including follicular lymphoma, diffuse large B-cell lymphoma, and platinum-resistant solid tumors. In addition to Tazemetostat, Epizyme is advancing other drug candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, and inhibitors targeting PRMT5 and PRMT1 for various solid tumors and blood cancers. The company collaborates with several prominent organizations in the pharmaceutical sector to enhance its research and development efforts.
BAKX Therapeutics
Series A in 2021
BAKX Therapeutics is a company focused on developing innovative cancer treatments. It specializes in creating orally active therapeutics that target the mitochondrial apoptosis pathway, which plays a crucial role in cell death and cancer progression. By leveraging insights into the dynamic protein structures involved in this pathway, along with advanced structure-based drug design and computational simulations, BAKX aims to enhance the effectiveness and longevity of cancer therapies. The company's approach seeks to provide medical professionals with improved treatment options for cancer patients.
Pyxis Oncology
Series B in 2021
Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.
Xilio Therapeutics
Series B in 2020
Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.
Pyxis Oncology
Series A in 2019
Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.
Clementia Pharmaceuticals
Acquisition in 2019
Clementia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Montreal, Canada, focused on developing innovative treatments for patients with ultra-rare bone disorders and other diseases. Founded in 2010, the company specializes in creating disease-modifying therapies to address high unmet medical needs. Its lead product candidate, palovarotene, is an oral small molecule that has demonstrated significant efficacy in preventing abnormal bone formation and fibrosis in various tissues. Currently, palovarotene is undergoing evaluation in the Phase III MOVE trial for conditions such as fibrodysplasia ossificans progressive and multiple osteochondromas, as well as dry eye disease. Clementia Pharmaceuticals aims to improve the lives of patients suffering from debilitating conditions through its advanced therapeutic solutions.
Merrimack Pharmaceuticals
Acquisition in 2017
Founded in 1993, Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts. It focuses on discovering, designing, and developing therapies for diseases, particularly in the areas of autoimmunity and cancer.
Rhythm Pharmaceuticals
Venture Round in 2017
Rhythm Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing peptide therapeutics for treating rare genetic disorders that cause life-threatening metabolic issues. Its lead product candidate, setmelanotide, is a potent melanocortin-4 receptor agonist designed for precision medicine to treat hyperphagia and severe obesity resulting from rare MC4R pathway diseases.
Akkadeas Pharma
Funding Round in 2017
Akkadeas Pharma srl, founded in 2007, is a Milan-based company specializing in the production and sale of pharmaceutical products, food supplements, and medical devices designed to alleviate symptoms that adversely affect patients' daily lives. The company offers a diverse range of products, including OVERSAL, BBTONIK-500, PERGRILL, OVERSAL FOLIC, SKRIM 1G, and TROFIGARD, aimed at enhancing individual well-being. In addition to its own product lines, Akkadeas Pharma also distributes third-party products. The company primarily markets its offerings through agents in Italy, targeting patients through their family doctors and specialists. With its foundation rooted in extensive experience in the pharmaceutical industry, Akkadeas Pharma aims to meet the needs of the private healthcare sector.
Rhythm Metabolic
Series A in 2015
Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.
OctreoPharm Sciences
Acquisition in 2015
OctreoPharm Sciences GmbH is a Berlin-based biopharmaceutical company specializing in the development of radiopharmaceuticals for the diagnosis and treatment of neuroendocrine tumors. Founded in 2010, the company is engaged in clinical development of theranostic antagonistic peptides specifically designed for tumor diagnosis and therapeutic control. Its key products include OPS201, which targets tumor cell-selective internal peptide receptor radionuclide therapy using 90Y or 177Lu, and OPS202, a novel 68 gallium-labeled somatostatin receptor antagonist intended for use in positron emission tomography. As of mid-2015, OctreoPharm Sciences operates as a subsidiary of Ipsen S.A.
Canbex Therapeutics
Acquisition in 2015
Canbex Therapeutics, Ltd. is a London-based company focused on developing peripherally-acting cannabinoid agonists aimed at treating spasticity associated with multiple sclerosis and other neurodegenerative diseases. Founded in 2005, the company addresses the debilitating symptoms of spasticity, which include involuntary muscle spasms and stiffness. Canbex Therapeutics strives to enhance the quality of life for individuals suffering from this serious and often incurable condition, with the objective of establishing a new standard in the treatment of spasticity.
Thesan Pharmaceuticals
Series B in 2014
Thesan Pharmaceuticals, Inc. is a biopharmaceutical company based in Carlsbad, California, that specializes in the development of novel therapeutics for skin disorders. Founded in 2011, the company is dedicated to creating innovative treatments for dermatological conditions, particularly atopic dermatitis and acne. Unlike many competitors who primarily focus on reformulating existing medications with limited advancements, Thesan aims to discover and develop new chemical entities that promise substantially improved therapeutic options for patients. This commitment to innovation addresses the growing need for effective solutions in a field that has seen relatively little progress in recent years.
Syntaxin
Acquisition in 2013
Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.
Motus Therapeutics
Series B in 2012
Motus Therapeutics is a biotechnology company located in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet needs in metabolic diseases. The company specializes in treatments for gastrointestinal disorders, with its lead product candidate, relamorelin, acting as a ghrelin agonist. Relamorelin is specifically designed for the treatment of diabetic gastroparesis, a gastrointestinal complication associated with diabetes, as well as other gastrointestinal functional disorders. Through its innovative approach, Motus Therapeutics aims to improve the quality of life for patients suffering from these conditions.
Rhythm Pharmaceuticals
Series B in 2012
Rhythm Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing peptide therapeutics for treating rare genetic disorders that cause life-threatening metabolic issues. Its lead product candidate, setmelanotide, is a potent melanocortin-4 receptor agonist designed for precision medicine to treat hyperphagia and severe obesity resulting from rare MC4R pathway diseases.
Motus Therapeutics
Series B in 2012
Motus Therapeutics is a biotechnology company located in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet needs in metabolic diseases. The company specializes in treatments for gastrointestinal disorders, with its lead product candidate, relamorelin, acting as a ghrelin agonist. Relamorelin is specifically designed for the treatment of diabetic gastroparesis, a gastrointestinal complication associated with diabetes, as well as other gastrointestinal functional disorders. Through its innovative approach, Motus Therapeutics aims to improve the quality of life for patients suffering from these conditions.
Biomeasure
Venture Round in 2011
Biomeasure, Inc., one of four research centers of the Ipsen Group to discover drugs in neuro-endocrinology, needed a multi-product, multi-purpose cGMP facility built on a fast track and a tight budget. Richmond started with a process to identify the goals of all Bio-measure stakeholders, continued with design & engineering coordination, achieved the budget through value engineering, and provided guaranteed costs & schedule. The results: 40,000 sf of cGMP manufacturing space, delivered in a short timeframe on a tight budget.
Syntaxin
Series C in 2010
Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.
Ipsen Pharmaceuticals
Acquisition in 2008
Ipsen Pharmaceuticals, Inc. provides pharmaceutical products.
Octagen
Acquisition in 2008
Octagen Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of drugs specifically designed to treat hemophilia and genetic disorders related to the clotting process. Established in 1997 and headquartered in Penn Valley, Pennsylvania, the company specializes in developing variations of recombinant B domain deleted porcine factor VIII, which are engineered to evade the immune system's inactivation. As of 2008, Octagen operates as a subsidiary of Ipsen S.A.
Tercica
Acquisition in 2008
Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA. The company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A.
Sterix
Acquisition in 2004
Sterix Ltd operates as a biopharmaceutical company that provides research and development services.
GENFIT
GENFIT is a late-stage biopharmaceutical company focused on discovering and developing innovative therapeutic and diagnostic solutions for metabolic and liver-related diseases with significant unmet medical needs. The company's expertise lies in targeting specific nuclear receptors and utilizing rational drug design, guided by the scientific leadership of Professor Bart Staels.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.